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Genetic Ablation of Orexin Neurons in Mice
Results in Narcolepsy, Hypophagia, and Obesity
differential cloning approach and named the putative
encoded peptides hypocretins. Orexin-A (hypocretin-1)
and orexin-B (hypocretin-2) are expressed together as
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feeding behavior, metabolic rate and arousal (Sakurai1Department of Pharmacology
et al., 1998; Lubkin and Striker-Krongrad, 1998; Hagan etInstitute of Basic Medical Sciences
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Recently, several reports implicate a dysfunction ofUniversity of Tsukuba
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lepsy. Narcolepsy is the only neurological disorder char-Japan
acterized by a primary disorganization of sleep and3 Howard Hughes Medical Institute
wakefulness. Patients with narcolepsy suffer from ex-4 Department of Pediatrics
cessive daytime sleepiness, cataplexy (a sudden weak-5 Department of Psychiatry
ening of posture muscle tone usually triggered by emo-6 Department of Molecular Genetics
tion), and an alteration in the amount of and entry intoUniversity of Texas
REM sleep (Mignot, 1998). Nocturnal sleep is also fre-Southwestern Medical Center at Dallas
quently disturbed by insomnia, sleep paralysis, and vividDallas, Texas 75390
dreaming. The debilitating lifelong disorder affects z1
in 2000 individuals. Familial transmission of narcolepsy
is rare; however, in these families the relative risk forSummary
first-degree relatives is 10 to 40 times higher than that
seen in the general population. One of the predisposingOrexins (hypocretins) are a pair of neuropeptides im-
factors is a specific class II HLA haplotype on humanplicated in energy homeostasis and arousal. Recent
chromosome 6, with HLA DQB1*0602 and DQA1*0102reports suggest that loss of orexin-containing neurons
alleles being found in more than 85% of all narcolepticoccurs in human patients with narcolepsy. We gener-
patients (Kadotani et al., 1998). The genetics of humanated transgenic mice in which orexin-containing neu-
narcolepsy, however, have remained unclear.rons are ablated by orexinergic-specific expression of
Positional cloning has identified mutations in thea truncated Machado-Joseph disease gene product
OX2R (hcrtr-2) gene as the cause of narcolepsy in a(ataxin-3) with an expanded polyglutamine stretch.
canine model (Lin et al., 1999), and mice with a targetedThese mice showed a phenotype strikingly similar to
deletion of the prepro-orexin gene display a phenotypehuman narcolepsy, including behavioral arrests, pre-
strikingly similar to human narcolepsy (Chemelli et al.,mature entry into rapid eye movement (REM) sleep,
1999). In contrast to monogenic murine and canine nar-poorly consolidated sleep patterns, and a late-onset
colepsy models, human narcolepsy is rarely familial, andobesity, despite eating less than nontransgenic lit-
may result from undefined environmental factors actingtermates. These results provide evidence that orexin-
on a susceptible genetic background (Mignot, 1998).containing neurons play important roles in regulating
Recently, it was demonstrated that orexin-A was unde-vigilance states and energy homeostasis. Orexin/
tectable in the cerebrospinal fluid (CSF) of the majorityataxin-3 mice provide a valuable model for studying
of patients with narcolepsy, indicating that abnormal
the pathophysiology and treatment of narcolepsy.
orexin neurotransmission also exists in human narco-
lepsy (Nishino et al., 2000). Since these patients do not
Introduction carry mutations in the prepro-orexin or orexin receptor
genes, decreased orexin levels in these patients may
Orexins are pairs of neuropeptides that are expressed result from dysfunction or loss of orexin-expressing neu-
in the lateral hypothalamic area (LHA), a region of the rons. More recently, postmortem studies in six narcolep-
brain classically implicated in feeding behavior (Sakurai tic subjects indicated undetectable orexin peptides in
et al., 1998). Orexin-A is a 33 amino acid residue poly- projection sites such as the cortex and pons and an
peptide with an N-terminal pyroglutamyl residue and 80%–100% reduction in the number of orexin-con-
C-terminal amidation. It has two intrachain disulfide brid- taining neurons in the hypothalamus as determined by
ges, while orexin-B is a 28 amino acid linear polypeptide in situ hybridization (Peyron et al., 2000). Thannickal et
with C-terminal amidation. The actions of orexins are al. (2000) independently reported a global loss of orexin-
mediated via two G protein-coupled receptors named containing neurons and residual gliosis in four brains
the orexin-1 (OX1R) and orexin-2 receptor (OX2R) (Sa- examined in the perifornical area of brains of narcoleptic
kurai et al., 1998). de Lecea et al. (1998) independently patients by immunohistochemistry. These results strongly
identified an mRNA encoding the same peptides by a suggest a selective loss of orexin-containing cells in
brains of narcoleptic patients. Thus, mice in which ore-
xin-containing neurons are specifically ablated would
7 Correspondence: stakeshi@md.tsukuba.ac.jp make a useful model of human narcolepsy. Furthermore,
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Figure 1. Expression of Truncated Ataxin-3
with Polyglutamine Repeat Stretch in Orexin-
Containing Neurons in Transgenic Mice
(A) Orexin/ataxin-3 transgene. The genomic
DNA fragment containing the 3149-bp
59-flanking region and the 122-bp 59-noncod-
ing region of exon 1 of human prepro-orexin
gene was ligated to a cDNA fragment, which
encodes from amino acid 286 to the C termi-
nus of elongated ataxin-3 isolated from a MJD
patient. The 59 terminus of this cDNA frag-
ment has the HA epitope and the 39 terminus
has the myc-epitope. The 39 end of ataxin-3
cDNA was followed by a murine protamine 1
genomic fragment (mPrm1) that provides an
intron and a polyadenylation signal. Southern
blot analysis of tail DNA from the F1 genera-
tion revealed that copy numbers ranged from
2 to 4 among lines.
(B) Double immunofluorescence photomicro-
graphs show matched coronal brain sections
(bregma 22.1 mm) of the lateral hypothalamic
area (LHA) of a 2-week-old orexin/ataxin-3
transgenic mouse (right panels) and trans-
gene-negative littermate (left panels). Orexins
are represented by green fluorescence (fluo-
rescein isothiocyanate) and myc epitope-
immunoreactivity is shown by red fluores-
cence (Cy-3). Lower panels show high power
views of the yellow-boxed areas in the upper
panels. Arrowheads indicate the existence of
nuclear aggregates stained by anti-myc anti-
body in orexin-containing neurons. Bar 5 100
mm for the upper panels, and 10 mm for the
lower panels.
the phenotype of such mice might be different from that Results
of prepro-orexin knockout mice because orexin neurons
Specific Expression of Polyglutamine Repeatof the LHA express several other neuropeptides includ-
in Orexin-Containing Neuronsing galanin (Hakansson et al., 1999), dynorphins (T. Chou
We constructed a transgene with the 3.2 kb fragmentand T. Scammell, personal communication), and angio-
of the 59-upstream region of the human prepro-orexintensin II (T. N., unpublished data).
gene as a promoter, which was ligated to the N terminallyWe have previously reported transgenic mouse lines
truncated cDNA for human ataxin-3 with 77 polygluta-in which the 3.2 kb fragment of the 59-upstream region
mine repeats. Additionally, we myc-tagged the C terminusof the human prepro-orexin gene is sufficient to express
of the transgene for histological examination (Figure 1A).the Escherichia coli beta-galactosidase (lacZ) gene eu-
The transgene was injected into pronuclei of fertilizedtropically in orexin containing neurons (Sakurai et al.,
mouse eggs to generate founder animals, which were1999). In the present study, we used the same human
bred to produce four orexin/ataxin-3 transgenic lines.prepro-orexin gene fragment as the promoter to specifi-
Brains from 2-week-old F1 orexin/ataxin-3 mice werecally express a toxic transgene only in orexin-containing
examined by double-immunofluoresence histochemis-neurons to selectively remove orexin-containing neu-
try using anti-myc monoclonal antibody and anti-orexin
rons in transgenic mice. This transgene, the N-terminal
antiserum to assess transgene expression. We ob-
truncated cDNA for human ataxin-3, which was isolated served a common expression pattern of specific myc-
from a patient with Machado-Joseph disease, includes like immunoreactivity in the hypothalamic orexin-con-
abnormally expended polyglutamine repeats, and has taining neurons in all lines (Figure 1B). These neurons
been shown to induce apoptosis in many cell types contained anti-myc positive nuclear aggregates (Figure
when expressed exogenously (Yoshizawa et al., 2000). 1B, right panels). No ectopic expression of myc-like
In these mice, hypothalamic orexin-containing neurons immunoreactivity was observed. These results suggest
gradually decrease in number, and are almost com- that this transgene directs expression of cDNA encoding
pletely absent by 15 weeks of age. We examined the the N terminally truncated human ataxin-3 with ex-
phenotype of these mice, focusing especially on abnor- panded polyglutamine repeats specifically in orexin
neurons.malities of sleep/wake states and energy homeostasis.
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Ablation of Orexin-Containing Neurons in the
Hypothalamus of Orexin/Ataxin-3 Mice
Brains of orexin/ataxin-3 mice showed a temporal pro-
gression of apparent loss of orexin-containing neurons
as determined by anti-orexin immunostaining. At post-
natal day 5 we were not able to detect any differences
in the number of orexin-containing neurons in orexin/
ataxin-3 mice and their wild-type littermates (data not
shown). However, we found that 56% 6 12% of orexin-
containing neurons were lost by 2 weeks of age (n 5 4)
(Figure 1B). Thereafter, 75% 6 5% and 90% 6 8% of
orexin-containing neurons were eliminated by 4 and 8
weeks of age, respectively (n 5 4) (Figure 2A). At 12
weeks of age, over 99% of orexin-containing neurons
were already lost (not shown), and at 15 weeks of age,
nearly no orexin-containing neurons could be found in
the hypothalamic regions of all lines. These observations
suggest that ablation of orexin-containing neurons oc-
curred postnatally, and most drastically within 2 weeks
after birth.
Immunostaining of progeny derived from all indepen-
dent transgenic founders confirmed that the ablation
of orexin-containing neurons occurred with full pene-
trance.
In situ hybridization of coronal sections of the mice
also revealed that prepro-orexin mRNA expression in
the LHA was markedly reduced in the transgenic mice
(Figure 2B)
Although orexin-containing cell bodies are exclusively
localized to the LHA, these neurons innervate regions
throughout the entire brain, including monosynaptic
projections to several regions of the cerebral cortex, the
limbic system, specific areas of the thalamus, and the
brain stem (Peyron et al., 1998; Date et al., 1999; Nambu
et al., 1999). We examined some of these projections in
orexin/ataxin-3 mice using anti-orexin antiserum, and
found that the number of orexin-immunoreactive fibers
was markedly decreased in the brains of the transgenic
mice. Notably, orexin-immunoreactive fibers in the locus
coeruleus, a region of the brain normally receiving dense
orexin neuronal projections, were markedly reduced in
transgenic mice (Figure 2C).
Gross anatomical and histological studies, using hem-
atoxyline-eosin and Nissl staining, failed to detect any
structural abnormality in the brains of the transgenic
mice at 12 weeks of age (not shown). Melanin-concen-
trating hormone (MCH)-containing neurons, a group of Figure 2. Ablation of Orexin Neurons in Orexin/Ataxin-3 Transgenic
Micelateral hypothalamic neurons that are distinct from ore-
xin-containing neurons (Elias et al., 1998), were immuno- (A) Matched brain sections (bregma 22.1 mm) from 4-, 8-, and 15-
week-old orexin/ataxin-3 transgenic mice (right panels) and theirstained in transgenic and wild-type control mice using
transgene negative littermates (left panels) were stained with anti-anti-MCH antiserum. The MCH-containing neurons were
orexin antiserum.unaffected by the presence of the transgene as the num-
(B) In situ hybridization of brain of orexin/ataxin-3 mouse (right panel)ber of MCH-positive cells was the same as that in the and their transgene negative control (left panel). Dark-field images
transgene-negative controls (Figure 3A). Northern blot of matched coronal brain sections of the LHA hybridized with
analysis revealed that the levels of MCH mRNA in orexin/ 33P-labeled antisense riboprobe for prepro-orexin mRNA. The signal
ataxin-3 were comparable with wild-type mice when was barely detectable in transgenic mice.
(C) Orexin-immunoreactive fibers in the locus coeruleus of annormalized by glyceraldehyde 3-phosphate dehydroge-
8-week-old orexin/ataxin-3 mouse (right panel) and its transgenenase (GAPDH) mRNA levels, while prepro-orexin mRNA
negative littermate (left panel) are shown. Note that orexin-immuno-levels in the hypothalamus of orexin/ataxin-3 mice were
reactive fibers are vastly removed in orexin/ataxin-3 mouse.
markedly reduced at 4 weeks of age (Figure 3B). After (D) Immunostaining of glial fibrillary acidic protein (GFAP)-like immu-
8 weeks of age, we could not detect prepro-orexin noreactivity in the LHA of a 12-week-old orexin/ataxin-3 mouse
mRNA in the hypothalamus of orexin/ataxin-3 mice of (right panel) and its transgene negative littermate (left panel) are
any lines by Northern analysis (not shown). Immuno- shown. There is no obvious difference between the two genotypes.
f, fornix. Bar 5 100 mmstaining for other hypothalamic peptides using anti-neu-
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Figure 3. Normal Expression of MCH in Ore-
xin/Ataxin-3 Mice
(A) Matched brain sections (bregma 22.1
mm) from an 8-week-old orexin/ataxin-3
transgenic mouse (lower panel) and a trans-
gene negative littermate (upper panel)
stained with anti-MCH antiserum. We ob-
tained similar results using the other trans-
genic lines. Bar 5 100 mm.
(B) Northern blot analysis for expression of
prepro-orexin mRNA of hypothalami from
4-week-old orexin ataxin mice of two inde-
pendent orexin/ataxin-3 lines and transgene-
negative mice (WT). The same blot was re-
rehybridized with MCH and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) probes.
ropeptide Y or anti-melanocyte-stimulating hormone narcoleptic episodes were identified in transgene-nega-
tive (wild-type) littermates.antibodies failed to detect any abnormality in the brains
of the transgenic mice (not shown). We also stained
brain sections of 12-week-old orexin/ataxin-3 mice with Sleep State Characterization
anti-glial fibrillary acidic protein (GFAP) antiserum, but of Orexin/Ataxin-3 Mice
we did not observe any evidence of gliosis in the hypo- Sleep state patterns of orexin/ataxin-3 mice and wild-
thalamus of orexin/ataxin-3 mice (Figure 2D). type littermate mice were revealed by simultaneous
Taken together, these observations suggest that ore- electroencephalographic/electromyographic (EEG/EMG)
xin-containing neurons are both postnatally and specifi- recording as previously reported (Chemelli et al., 1999).
cally removed in orexin/ataxin-3 transgenic mice. Typical hypnograms, graphic representations of sleep-
waking states over time, for an orexin/ataxin-3 mouse
and a wild-type littermate for the 12 hr dark period (activeBehavioral Arrests in Orexin/Ataxin-3
Mice in the Dark Period phase) are shown in Figure 5A. The hypnogram for the
transgenic mouse is characterized by the appearanceSince mice are most active at night, we observed noctur-
nal behavior of orexin/ataxin-3 mice and wild-type lit- of direct transitions from wakefulness to REM sleep, and
more fragmented waking and non-REM sleep episodestermate mice by infrared video photography. Frequent
periods of obvious behavioral arrest were observed in (Figure 5A). A typical example of an EEG/EMG recording
showing the direct transition from the awake state toorexin/ataxin-3 mice, similar to the “narcoleptic epi-
sodes” in prepro-orexin knockout mice (Chemelli et al., REM sleep is depicted in Figure 5B. The mean 6 SEM
frequency of direct transition to REM observed in orexin/1999). As previously reported, such episodes were rec-
ognized in orexin/ataxin-3 mice by an abrupt cessation ataxin-3 mice for 12 hr light and dark period was 0.25 6
0.16 and 3.17 6 1.45, respectively (n 5 4 for 3 days).of purposeful motor activity associated with a sustained
change in posture that was maintained throughout the No direct REM transition was ever observed in wild-type
littermates.episode, ending abruptly with complete resumption of
purposeful motor activity (Chemelli et al., 1999). The Sleep state patterns of orexin/ataxin-3 mice were very
similar to that of prepro-orexin knockout mice (Chemellipostural changes are characterized by sudden collapse
of the head and neck with simultaneous buckling of the et al., 1999), despite some differences in the genetic
background. During the dark period, both REM sleeplimb. An infrared video study of progeny derived from
three independent transgenic lines confirmed that this time and REM episode duration were longer in the trans-
genic mice (n 5 4) compared to wild-type littermatesbehavior occurred with 100% penetrance in orexin/
ataxin-3 mice (n 5 6 for each line). 12-week-old trans- (n 5 3) (Table 1). These changes occurred together with a
decrease in the interval between successive REM sleepgenic mice had from 10 to 30 episodes during the 4 hr
filming period (group average 20 6 6.6 episodes) (Figure periods, indicating increased pressure for entry into
REM sleep in these mice. There was also a significant4A). The duration of episodes varied from a few seconds
to 150 s. Overall, the average duration of episodes was decrease in awake episode duration, reflecting an in-
creased fragmentation of the sleep-wake cycle and an41.4 s. As with prepro-orexin knockout mice, attacks
often occurred during grooming or excited ambulation inability to maintain consolidated wakefulness during
the dark period in orexin/ataxin-3 mice (Figure 5A, Table(Figure 4B). Similar to prepro-orexin knockout mice,
feeding and drinking were rarely observed before an 1). REM latency was also significantly shorter in orexin/
ataxin-3 mice compared with wild-type littermates dur-episode, but were frequently observed afterward. These
behavioral arrests typically began at about 6 weeks of ing the dark period.
During the light period time spent in REM sleep andage. We obtained similar results from transgenic mice
of the two other lines (not shown). We observed similar the episode duration of the awake state was significantly
shorter in orexin/ataxin-3 mice as compared with theirepisode frequency and duration in both genders. No
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Figure 4. Characterization of Behavioral Arrests in Orexin/Ataxin-3
Mice
(A) Behavioral arrest (narcoleptic episode) number and duration.
Columns represent total number of episodes recorded in the first 4
hr after onset of dark period. Filled circles represent mean duration
of all recorded episodes. T-bars indicate the minimum and maximum
episode durations observed. Data for individual male transgenic
mice are designated A-F. No narcoleptic cataplexy-like episodes
were observed in any of the wild-type mice (n 5 6). Group is the
average count and duration for all mice (A-F), with the T bars indica-
Figure 5. Sleep State Abnormalities Seen in Orexin/Ataxin-3 Mice
tive of minimum and maximum individual averages.
(A) Representative 12 hr dark period (20:00 to 08:00) hypnogram for(B) Behavior of orexin/ataxin-3 mice before and after each narcolep-
an orexin/ataxin-3 mouse (upper panel) and its transgene-negativetic episode. The predominant behavior observed for the 5 s preced-
littermate (lower panel). The height of the horizontal line above base-ing each episode and the predominant behavior for the 10 s after
line indicates the vigilance state of the mouse at the time. W, wake-each episode were categorized as previously reported (Chemelli et
fulness; NR, non-REM sleep; R, REM sleep. Note episodes of directal., 1999). Number of observations and percentage of total observa-
transition from awake state to REM sleep (marked by arrowheads),tions are reported.
greater non-REM sleep episode fragmentation, and reduced wake-
fulness periods in the hypnogram of the orexin/ataxin-3 mouse.
Hypnograms were obtained by simultaneous EEG/EMG recording
wild-type counterparts (Table 1). Direct transitions from as described previously (Chemelli et al., 1999).
waking to REM were also occasionally observed in the (B) EEG/EMG simultaneous recoding showing a typical example of
a direct transition from awake state to REM sleep, extracted fromlight period.
a continuous record. Awake state, which is characterized by a high-
amplitude EMG and a low amplitude, mixed frequency EEG, is di-
Orexin Neuron-Ablated Mice Exhibit Late-Onset rectly followed by a REM sleep episode, which is characterized by
muscle atonia, leaving only the heart beat registering on the EMG,Obesity despite Being Hypophagic
combined with a low-amplitude EEG dominated by theta-frequen-We found that orexin/ataxin-3 mice showed late-onset
cies. The arrowhead indicates a sleep spindle, which is sometimesobesity (Figures 6A and 6B). At 10 to 12 weeks of age,
seen shortly before or at the entry into REM sleep periods in rodents.
the male transgenic mice started to gain excess weight
(Figure 6B). Female transgenic mice displayed a similar
pattern of obesity (not shown). Obesity occurred despite these mice must be decreased. As lower energy expen-
diture may result from differences in motor activity, wean almost 30% reduction in food intake during the dark
period at 8 to 10 weeks of age, suggesting the impor- measured spontaneous motor activity, using an infrared
ambulation monitoring system (Masuo et al. 1997). Wild-tance of orexin-containing neurons in the regulation of
feeding behavior and energy homeostasis (Figure 6C). type mice showed a higher level of spontaneous activity
than orexin/ataxin-3 mice for most of the dark period,Since orexin/ataxin-3 mice became obese despite
eating less, we speculated the energy expenditure of while no obvious difference between genotypes was
Neuron
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Table 1. Vigilance State Parameters Recorded from Orexin/Ataxin-3 Hemizygous Transgenic (Tg) and Wild-Type Littermate Control (WT) Mice
REM Sleep Non-REM Sleep Awake
Tg WT Tg WT Tg WT
24 hr
Total time (min) 88.2 6 3.5 91.6 6 2.3 731.4 6 7.9 692.1 6 15.3 617.7 6 6.6 653.7 6 15.7
Episode duration (s) 80.4 6 2.1* 70.3 6 2.9 265.8 6 10.7 298.3 6 17.1 252.0 6 11.8* 383.5 6 14.4
REM latency (min) 6.4 6 0.3* 9.4 6 0.5
Inter-REM interval (min) 20.8 6 1.2 17.1 6 0.7
Light Period
Total time (min) 41.8 6 1.8* 64.4 6 2.3 443.6 6 5.1 428.6 6 4.6 233.3 6 5.1 225.7 6 5.6
Episode duration (s) 75.7 6 2.8 72.8 6 3.5 363.8 6 15.8 309.6 6 16.0 265.0 6 10.7* 310.1 6 13.4
REM latency (min) 9.0 6 0.4 9.7 6 0.4
Inter-REM interval (min) 22.0 6 1.2* 16.5 6 0.8
Dark Period
Total time (min) 46.4 6 2.0* 27.1 6 3.3 287.9 6 9.6 263.6 6 14.4 384.4 6 9.1 428.0 6 17.1
Episode duration (s) 85.7 6 2.8* 67.1 6 5.6 188.7 6 8.8 282.7 6 21.5 247.0 6 17.6* 474.7 6 32.9
REM latency (min) 4.5 6 0.4* 9.2 6 0.6
Inter-REM interval (min) 19.8 6 1.0 19.2 6 1.1
Total time spent in each state (minutes, mean 6 SEM), episode duration (seconds 6 SEM), REM latency, and interval between successive
REM sleep episodes (minutes, mean 6 SEM) over 24 hr and itemized separately for light and dark periods.
Significant differences (p , 0.05; repeated measurements ANOVA) between Tg and WT mice are indicated with an asterisk.
observed in the light period, consistent with a lower Postnatal Loss of Orexin-Containing Neurons
in Mice Results in Narcolepsyenergy expenditure in transgenic mice over the recorded
The first clue suggesting the possible involvement of24 hr period (Figure 6D).
the orexin system in narcolepsy came from animal mod-
els. The positional cloning approach in the canine narco-
Discussion
lepsy model led to the identification of mutations in
the OX2R (hcrtr2) gene (Lin et al., 1999). Independently,
Technical Considerations prepro-orexin knockout mice were reported to exhibit
An understanding of the functions of the brain, which episodes of behavioral arrest similar to cataplexy and
depends on neuron-neuron interactions, will progress have fragmented sleep/wake pattern during the dark
with the development of methods that permit the selec- period (Chemelli et al., 1999). In humans, however, most
tive elimination of neuronal types with particular chemi- cases of narcolepsy are not monogenic. Although a mu-
cal identities. When ablation of a subpopulation of neu- tation screening of prepro-orexin OX1R and OX2R genes
rons leads to physiological and behavioral changes, it was carried out on 74 patients with a family history of
is possible to determine the role of a specific type of narcolepsy, only one mutation has been identified so
neurons in brain function. General methods of genetic far, in a highly atypical patient with symptomatic onset
cell ablation are based on expression of a toxic gene at 6 months of age (Peyron et al., 2000). Interestingly,
product under the control of a cell-specific enhancer/ the early presentation of this particular case was similar
promoter (Palmiter et al., 1987). The diphteria toxin gene to genetically induced narcolepsy in animals and there-
product is widely used for this purpose in nonneuronal fore different from most cases of human narcolepsy,
cell lineage. An alternative approach is conditional oblit- which usually start during adolescence (Bassetti and
eration of target cells with herpes simplex virus 1 thymi- Aldrich, 1996). Recent reports indicated that narcoleptic
dine kinase (Heyman et al., 1989). However, these tech- human brains have undetectable prepro-orexin mRNA
niques have not been used to eliminate postmitotic cells, and markedly reduced immunocytochemical staining of
including neurons, because these toxins may not be orexin peptides in the perifornical area (Peyron et al.,
adequately effective in neurons. 2000; Thannickal et al., 2000), supporting an earlier re-
We used a C-terminal fragment of ataxin-3 gene prod- port showing undetectable CSF orexin-A levels in most
uct, which was isolated from a Machado-Joseph dis- narcolepsy patients (Nishino et al., 2000). These results
ease patient to ablate orexin-containing neurons. This suggest either a loss of orexin-containing neurons or a
cDNA product has been shown to induce apoptosis in lack of orexin production in these neurons if still present.
many cell types when expressed exogenously in vitro Thannickal et al. (2000) reported that global loss of ore-
(Yoshizawa et al. 2000). We showed that expression of xin-immunoreactive neurons was accompanied by re-
this cDNA effectively removes orexin-containing neu- sidual gliosis in the perifornical area. With the well-
rons in vivo in transgenic mice. This method should established HLA association of narcolepsy (Kadotani et
be broadly applicable in genetic ablation of a defined al., 1998), these observations suggest an autoimmune
population of neurons, and provides an approach to mediation of human narcolepsy with highly selective
elucidate the physiological and behavioral functions of destruction of orexin-containing cells in the disorder.
specific neuronal types in the mammalian central ner- This mechanism would be consistent with the hypothe-
vous system. It could also be used to create experimen- sis that narcolepsy is caused by environmental factors
tal models of human brain disorders that are caused by that act on a susceptible genetic background (Mignot,
1998). Since orexin-containing neurons in the LHA ex-degeneration of certain neuronal groups.
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Figure 6. Abnormality in Energy Homeostasis Observed in Orexin/Ataxin-3 Transgenic Mice
(A) Photograph showing an 18-week-old orexin/ataxin-3 mouse (left) and its nontransgenic littermate (right). Note obvious obesity in the orexin/
ataxin-3 mouse.
(B) Growth curves of wild-type (n 5 8) and orexin/ataxin-3 mice (n 5 8). *From 12 to 15 weeks, p , 0.05; from 16 weeks onward, p , 0.01.
(C) Food consumption in wild-type and orexin/ataxin-3 mice at 8 to 10 weeks of age, p , 0.002 (n 5 8).
(D) Spontaneous motor activity of 10- to 12-week-old orexin/ataxin-3 mice (Tg) and their transgene-negative littermates (WT) measured by
infrared monitoring system (Supermex system; Muromachi Kikai). Measured activity during 15 min intervals are plotted. Data are indicated
as mean 6 S.E. (n 5 24). Inset shows counted activity during 24 hr in orexin/ataxin-3 mice (Tg) and transgene-negative littermates (WT). p ,
0.001 (n 5 24). Statistical analyses were performed with ANOVA (two-way layout with repetition).
press other neuropeptides (Hakansson, et al., 1999), loss similarity of these two mouse models further demon-
strates the importance of orexins in the regulation ofof these neurons might produce a phenotype distinct
from that of prepro-orexin deficiency. Moreover, postna- the sleep/wake state. Our observations also suggest,
that although orexin-containing neurons produce othertal loss of orexins might result in a different phenotype
compared with the prepro-orexin knockout mice that neuromodulators, it is orexin that is important for the
regulation of the sleep/wake state by these neurons.do not produce orexins at any stage of their lives.
In the present study, we generated mice in which The behavioral arrests seen in orexin/ataxin-3 mice
typically began about 6 weeks of age. We never ob-orexin-containing neurons are genetically ablated to ex-
amine the phenotype caused by postnatal loss of orexin- served these episodes earlier than 6 weeks of age in
any lines of orexin/ataxin-3 mice. On the other hand,containing neurons. These mice exhibited a phenotype
strikingly similar to human narcolepsy, including cata- attacks were observed in some prepro-orexin knockout
mice earlier than 3 weeks of age (Chemelli, et al., 1999).plexy-like behavioral arrests, premature onset of REM
periods, fragmented wake and non-REM sleep epi- We observed one fourth of orexin-containing neurons
still exist in the hypothalamus of orexin/ataxin-3 micesodes, and increased body weight.
The orexin/ataxin-3 mice exhibited sleep abnormali- at 4 weeks of age (Figure 2A). Residual orexin-containing
neurons in orexin/ataxin-3 mice might function to pre-ties strikingly similar to that of prepro-orexin knockout
mice despite their different genetic backgrounds (Ore- vent the emergence of the behavioral arrests. Thus,
postnatal loss of orexin-containing neurons is morexin/ataxin-3 mice in this study are 75% C57BL/6 and
25% DBA1, while prepro-orexin knockout mice reported comparable to the typical narcolepsy syndrome in hu-
mans, which usually starts at adolescence.previously are 50% C57BL/6 and 50% 129SvEv). The
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Other than the timing of phenotypical emergence, we raphe nucleus, ventral tegmental area, and locus coeru-
leus, as well as direct or indirect inhibition of the VLPO.did not observe significant differences in the character-
istics of behavioral arrests seen in orexin/ataxin-3 mice Consistent with this, pharmacological studies of canine
narcolepsy have suggested that narcolepsy is associ-and prepro-orexin knockout mice. In particular, average
episode frequency in the first 4 hr of the dark period is ated with hyperactivity of cholinergic neurotransmission
and decreased monoaminergic tone, which are consis-20 6 6.6 episodes; the duration of episodes varied from
a few seconds to 150 s (Figure 4A). These are similar tent with narcoleptic symptoms including daytime
sleepiness and REM abnormalities (Mignot et al., 1993).findings to those reported in prepro-orexin knockout
mice (Chemelli et al., 1999). Although the overall average Our present observations that orexin neuron-ablated
mice lose projections to sleep/wake nuclei and exhibitduration of episodes was 42.4 s, shorter than that re-
ported in prepro-orexin knockout mice (65.6 s) (Chemelli behavioral arrests resembling cataplexy, a tendency to-
ward premature entry into REM sleep, and poorly con-et al., 1999), this discrepancy likely stems from small
sample sizes and high variability of individual episode solidated sleep patterns, unequivocally indicate the es-
sential nature of orexin-containing neurons in thedurations among and between the orexin/ataxin-3 and
prepro-orexin knockout mouse cohorts studied. As with maintenance of the waking state and a proper architec-
ture of sleep/wake cycles.prepro-orexin null mice, attacks often occurred during
grooming or excited ambulation, implicating the animal’s
emotional state in the onset of episodes (Figure 4B). Obesity in Orexin/Ataxin-3 Mice
Sleep state patterns of orexin/ataxin-3 mice revealed A significant body of evidence has been accumulated
by simultaneous EEG/EMG recording were very similar for a role of orexins in the regulation of energy metabo-
to that of prepro-orexin knockout mice (Chemelli et al., lism and autonomic function (reviewed in Willie et al.,
1999), despite some differences in the genetic back- 2001). Besides increasing feeding behavior in a dose-
ground. However, we observed the duration of awake dependent manner (Sakurai et al., 1998), central injec-
state during the light period was significantly shorter in tion of orexin-A increases oxygen consumption in mice
orexin/ataxin-3 mice as compared with wild-type lit- indicating an increased metabolic rate (Lubkin and
termates (Table 1), a difference that was not observed Stricker-Krongrad, 1998). Orexins also increase mean
in prepro-orexin knockout mice (Chemelli et al., 1999). arterial blood pressure and heart rate in rats when ad-
Although these differences might be due to small sample ministered into the lateral ventricle or ventrolateral me-
sizes and divergent genetic backgrounds of the trans- dulla, suggesting positive influences on sympathetic
genic and knockout mice studied, the finding of sleep outflow (Samson et al., 1999; Chen et al., 2000; Shirasaka
abnormalities during the daytime in orexin/ataxin-3 mice et al., 1999). These effects generally result in increased
is more consistent with human narcolepsy, in which energy consumption.
sleep disruptions also occur during the rest phase Metabolic abnormalities in food intake and/or energy
(night). expenditure may exist in human narcolepsy. This is evi-
denced by increased frequencies of obesity and nonin-
sulin dependent (Type II) diabetes in narcoleptic patientsRole of Orexin-Containing Neurons in Maintenance
of the Sleep/Wakefulness State compared with a control group (Schuld et al., 2000;
Honda et al., 1986). Orexin/ataxin-3 mice showed late-Orexin-containing neurons have been shown to heavily
innervate those brainstem and hypothalamic regions im- onset obesity (Figures 6A and 6B), consistent with hu-
man cases. However, food consumption of orexin/plicated in regulation of sleep/wake state. Such regions
include the pedunculopontine and laterodorsal tegmen- ataxin-3 mice was decreased by almost 30% at 8 to
10 weeks of age (Figure 6C), before obesity becametal nuclei, locus coeruleus, dorsal raphe nucleus, ventral
tegmental nucleus, and tuberomammillary nucleus apparent. Thus, reduced food intake is unlikely to be a
simple compensation for increased weight gain. Rather,(Chemelli et al., 1999; Nakamura et al., 2000). These
neurons diffusely innervate cerebral cortices and thala- reduced feeding and obesity may together reflect an
underlying reduction in energy expenditure due to de-mocortical neurons to maintain arousal (Saper, 1987).
Indeed, orexins activate adrenergic cells from the lo- creased motor activity, a lower basal metabolic rate, or
both. Indeed, we observed a decreased spontaneouscus coeruleus (Hagan et al., 1999) and dopaminergic
cells from the ventral tegmental area in vitro (Nakamura motor activity in the dark (active) period in orexin/ataxin-
3 mice (Figure 6D). Decreased basal energy expenditureet al., 2000). Additionally, orexin neurons and monoami-
nergic neurons directly innervate the preoptic area of the may result directly from elimination of orexin-containing
neurons, which normally promote energy expenditure.hypothalamus, the location of the ventrolateral preoptic
nucleus (VLPO). The VLPO is thought to modulate the The metabolic abnormality in orexin/ataxin-3 mice
seems more severe than that of prepro-orexin knockoutonset of sleep via sleep-promoting neurons that can be
inhibited in vitro by noradrenaline, acetylcholine and mice reported by Chemelli et al. (1999). Prepro-orexin
knockout mice reportedly display normal growth ratherserotonin (Gallopin et al., 2000). The orexin system might
interact directly with VLPO neurons, or indirectly via than obesity, although they are also hypophagic (Che-
melli et al., 1999; Willie et al., 2001). The observed meta-monoamines and acetylcholine.
Maintenance of arousal by orexin-containing neurons bolic differences between orexin/ataxin-3 mice and pre-
pro-orexin knockout mice may stem from differentmay thus be achieved by coordinated regulation of the
cholinergic systems in the pedunculopontine nucleus genetic backgrounds and environmental effects. In-
deed, metabolic phenotypes are known to be very sensi-and laterodorsal tegmental nucleus, and the monoami-
nergic systems in the tuberomammillary nucleus, dorsal tive to genetic background and environmental factors.
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generate N1 mice, which we used for characterization. The presenceLoss of neuropeptides or modulatory factors expressed
and copy numbers of the transgene in the offspring were identifiedby orexin-containing neurons may also contribute to
by tail blot and PCR analysis using tail DNA. Four transgenic linesphenotypic differences in these models. In particular,
were established.
dynorphins, which influence feeding behavior (Walker
et al., 1980). Another intriguing possibility is that pheno- Histological Analysis
typic differences result in part from fetal and/or early Mouse brains were fixed and prepared as described previously
(Nambu et al., 1999). For double immunofluorescence analysis, cryo-postnatal development in the presence or absence of
stat sections (40 mm) were cut and post-fixed with paraformalde-orexin signaling in orexin/ataxin-3 mice and knockout
hyde, incubated with 1% bovine serum albumin in phosphate-buf-mice, respectively. Additional metabolic and activity
fered saline (PBS) for 1 hr, and then incubated with rabbit anti-orexinstudies of these two narcoleptic mouse models, under
antiserum (Nambu et al., 1999) and mouse anti-myc monoclonal
identical environmental and genetic conditions, may antibody (9E10; Santa Cruz) in the same solution for 1 hr at room
clarify these issues. temperature. After washing three times in PBS, the sections were
incubated with FITC-conjugated goat anti-rabbit IgG and Cy-3-con-
jugated donkey anti-mouse IgG antibodies (Cappel) for 1 hr at roomConclusion
temperature. The slides were then washed three times in PBS andRecent observations suggest that narcolepsy is a neuro-
examined under a fluorescence microscope. For the other immuno-degenerative disorder that specifically affects orexin-
stainings, cryostat sections (40 mm) were stained using the avidin-
containing neurons (Peyron et al., 2000; Thannickal et biotin-peroxidase method as described previously (Nambu et al.,
al., 2000). As orexin-containing neurons normally ex- 1999). For determining numbers of orexin-containing neurons or
MCH-containing neurons, we counted orexin- or MCH-immunoreac-press additional neuropeptides, we probed whether
tive neurons in five coronal sections throughout the hypothalamicmice with selective postnatal degeneration of orexiner-
region containing these neuronal populations. For in situ hybridiza-gic neurons differ phenotypically from prepro-orexin
tion histochemistry, a 0.29 kb segment of mouse cDNA encodinggene knockout mice, in which development occurs in the
Gln33-Val130 of prepro-orexin was generated by PCR and sub-
absence of orexin signaling, and residual neuropeptide cloned into pBluescript II SK (1) vector. Sense and anti-sense ribo-
functions of these neurons may be intact. As is likely probes were generated with T7 and T3 RNA polymerases, respec-
tively in the presence of 33P-CTP (Amersham). In situ hybridizationthe case in human narcolepsy, orexin/ataxin-3 mice are
of the adult mouse brain sections was performed as describedborn with orexins but loose orexin-containing neurons
previously (Chemelli et al., 1999).later in life. Accordingly, the onset of narcoleptic attacks
in orexin/ataxin-3 mice is later than in prepro-orexin
Infrared Videotaping and Scoring of Narcoleptic Episodesknockout mice. We also observed late-onset obesity in
A digital CCD video camera with infrared capability (Sony DCR-PC3)
orexin/ataxin-3 mice. was used for documentation and scoring of dark cycle behavior of
Our findings confirm the importance of orexinergic male mice at 10 to 12 weeks of age. Food and water were available
ad libitum. The first 4 hr of the dark phase were videotaped fromneurons in the regulation of sleep/wake states and fur-
overhead for all behavioral paradigms described. Two independentther suggest a role in metabolic regulation. Orexin/
observers blinded for genotype scored open field narcoleptic epi-ataxin-3 mice may represent the most accurate patho-
sodes. Narcoleptic episodes for all experimental paradigms werephysiological model of narcolepsy available; this model
strictly defined by the criteria described previously (Chemelli et al.,
should be valuable in the study of the symptoms, genet- 1999) ( i.e., [a] an abrupt transition from obvious purposeful motor
ics, and therapy of this debilitating human sleep disor- activity, [b] a sustained change in posture maintained throughout
the episode, and [c] an abrupt end to the episode with resumptionder. Our findings confirm the importance of orexinergic
of obvious purposeful motor activity).neurons in the regulation of sleep/wake states and fur-
ther suggest a role in energy homeostasis.
Spontaneous Motor Activity
Spontaneous motor activity of male mice (10 to 12 weeks of age) wasExperimental Procedures
continuously measured individually in a home cage with a Supermex
system (Muromachi Kikai, Japan). In this system, a sensor detectsAnimal Use
the radiated body heat of an animal (Masuo et al., 1997). We mea-All experimental procedures involving animals were approved by
sured activity counted by this system during each 15 min for fourthe University of Tsukuba Animal Care and Use Committee and the
consecutive 24 hr periods. Food and water were replenished atInstitutional Animal Care and Research Advisory Committee of the
08:00, and mice were not otherwise disturbed in any way. Six miceUniversity of Texas Southwestern Medical Center at Dallas, and
were recorded concurrently in matched littermate pairs of the trans-were in accordance with NIH guidelines.
genic and wild-type controls.
Generation of Transgenic Mouse Lines
Truncated ataxin-3 cDNA with 77 repeats of polyglutamine was EEG/EMG Recording
Male mice (14 weeks old) were anesthetized and chronically im-donated by Dr. Yoshizawa. This cDNA fragment encodes from amino
acid 286 to the C terminus of elongated ataxin-3 from a Machado- planted for continuous monitoring of EEG/EMG as described pre-
viously (Chemelli et al., 1999). Animals were housed in a 12 hr light/Joseph disease patient (Yoshizawa et al., 2000), and was subcloned
between HindIII and KpnI sites of pcDNA3.1 myc-His (Invitrogen) dark cycle and allowed to habituate to recording conditions for 2
weeks. Each mouse was then recorded for three consecutive 24 hr(pMJD-Q77 (DN286)). The transgene, termed orexin/ataxin-3, was
constructed by swapping the HindIII-PmeI fragment of pMJD- periods, beginning at lights-on at 08:00. Food and water were re-
plenished at 8:00 a.m., and the mice were not otherwise disturbedQ77(DN286) for the nLacZ gene (SalI-BamHI) fragment of the orexin-
nlacZ transgene (Sakurai et al., 1999). As a consequence, the 39 end in any way. Four male transgenic mice and three matched wild-
type littermates were recorded concurrently. EEG/EMG signals wereof this DNA fragment was followed by murine protamine-1 (mPrm1)
gene fragment (from 195 relative to the transcription start site to amplified using a Grass Model 78 (Grass Instruments, West War-
wick, RI) and filtered (EEG: 0.3–100 Hz, EMG: 30–300 Hz) before1625), which includes part of exon 1 and all of intron 1 and exon
2 including the polyadenylation signal and site. The transgene was being digitized at a sampling rate of 250 Hz, and displayed on a
polygraph system. EEG/EMG records were visually scored into 20linearized and microinjected into fertilized mouse eggs (BDF1 strain,
which is the F1 of C57BL/6 and DBA1) to generate transgenic s epochs of wakefulness, REM, and non-REM sleep according to
standard criteria of rodent sleep (Radulovacki et al., 1984).founder lines. Founder animals were mated with C57BL/6 mice to
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